核受体TR3/Nur77与肿瘤治疗  

Nuclear Receptor TR3/Nur77 and Cancer Therapy

作　　者：王维嘉[1] 王渊[1] 吴乔[1] 

机构地区：[1]厦门大学细胞应激生物学国家重点实验室,厦门361102

出　　处：《中国细胞生物学学报》2015年第5期604-615,共12页Chinese Journal of Cell Biology

摘　　要：核孤儿受体TR3(也称Nur77)是NR4A1编码的立早基因产物,属于类固醇/甲状腺受体/视黄酸受体超家族成员。TR3广泛参与各种生命活动过程,如细胞生长、分化、凋亡和自噬等调控,被认为是良好的抗肿瘤药物设计靶标。TR3不仅作为转录因子通过结合DNA应答元件调控基因的转录和表达,而且还能作为调节蛋白通过蛋白相互作用和亚细胞不同定位发挥独特的作用。该文重点综述了TR3在肿瘤发生发展中的功能和调控机制,及以TR3为靶标治疗肿瘤的药物研究进展。Orphan nuclear receptor TR3 （also known as Nur77） is a product of an immediate-early gene encoded by NR4A1, and belongs to the steroid/thyroid/retinoid nuclear receptor superfamily. TR3 is widely involved in the regulation of biological processes, such as cell proliferation, differentiation, apoptosis and autophagy. It is considered as an important molecular target for anti-tumor drug design. TR3, as a transcription factor, regulates gene transcription and expression through targeting to the DNA response elements, and alsofunctions as a regulator through interaction with other proteins in distinct subcellular localizations. Here, we review the functions and regulatory mechanisms of TR3 in tumorigenesis, and progress in the development of therapeutics with TR3 as the target.

关 键 词：孤儿核受体 TR3/Nur77 肿瘤治疗 凋亡 自噬 

分 类 号：R730.5[医药卫生—肿瘤]